Companies have halted an advanced trial of an HIV vaccine because the shot was found to not prevent infection.
Results from the stage 3 trial led to the determination that the vaccine “was not effective in preventing HIV infection compared to placebo among study participants,” Johnson & Johnson and its partners said in a statement.
The vaccine, dubbed Mosiaco, was developed by Janssen, a Johnson & Johnson subsidiary.
The study’s Data and Safety Monitoring Board, or a group of independent experts that was monitoring the research, made the determination.
The study is being discontinued because of the determination, Johnson & Johnson said….